DK1532141T3 - 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv - Google Patents

2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv

Info

Publication number
DK1532141T3
DK1532141T3 DK03794933.6T DK03794933T DK1532141T3 DK 1532141 T3 DK1532141 T3 DK 1532141T3 DK 03794933 T DK03794933 T DK 03794933T DK 1532141 T3 DK1532141 T3 DK 1532141T3
Authority
DK
Denmark
Prior art keywords
antidepressants
pyrrolidin
oxadiazole derivatives
oxadiazole
derivatives
Prior art date
Application number
DK03794933.6T
Other languages
Danish (da)
English (en)
Inventor
Hagen-Heinrich Hennies
Helmut Buschmann
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK1532141T3 publication Critical patent/DK1532141T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK03794933.6T 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv DK1532141T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10240818A DE10240818A1 (de) 2002-08-30 2002-08-30 Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
PCT/EP2003/009390 WO2004024725A1 (de) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivate und ihre verwendung als antidepressiva

Publications (1)

Publication Number Publication Date
DK1532141T3 true DK1532141T3 (da) 2010-11-22

Family

ID=31983895

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03794933.6T DK1532141T3 (da) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv

Country Status (18)

Country Link
US (1) US7105538B2 (enExample)
EP (1) EP1532141B1 (enExample)
JP (1) JP2006506348A (enExample)
CN (1) CN100390168C (enExample)
AR (1) AR041093A1 (enExample)
AT (1) ATE484503T1 (enExample)
CA (1) CA2497078A1 (enExample)
CY (1) CY1110913T1 (enExample)
DE (2) DE10240818A1 (enExample)
DK (1) DK1532141T3 (enExample)
ES (1) ES2351119T3 (enExample)
MX (1) MXPA05002298A (enExample)
PE (1) PE20040983A1 (enExample)
PL (1) PL375627A1 (enExample)
PT (1) PT1532141E (enExample)
RU (1) RU2324694C2 (enExample)
SI (1) SI1532141T1 (enExample)
WO (1) WO2004024725A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2291080E (pt) 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
RU2417995C1 (ru) * 2009-09-21 2011-05-10 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") Способ получения 3-(2-замещенных-1,3-оксазол-4-ил)пиридин-2(1н)-онов
CN103420998A (zh) * 2012-05-16 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种新型噁二唑衍生物的合成方法
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
BR112015007516A2 (pt) * 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CN105051040A (zh) * 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
CN103333165B (zh) * 2013-07-01 2016-02-24 河南理工大学 2-苯基-5-(3,4-二甲基)吡咯基-1,3,4-噁二唑及制备方法
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2215949B1 (enExample) * 1973-02-01 1976-07-02 Delalande Sa
US4784998A (en) * 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
CN1382140A (zh) * 1999-07-09 2002-11-27 奥索-麦克尼尔药品公司 具有神经营养活性的吡咯烷和哌啶、以及含有它们的相关组合物
JP2001247569A (ja) * 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives

Also Published As

Publication number Publication date
MXPA05002298A (es) 2005-06-08
JP2006506348A (ja) 2006-02-23
PT1532141E (pt) 2010-11-02
EP1532141B1 (de) 2010-10-13
SI1532141T1 (sl) 2010-12-31
CN1678609A (zh) 2005-10-05
ES2351119T3 (es) 2011-01-31
US20050187260A1 (en) 2005-08-25
CA2497078A1 (en) 2004-03-25
US7105538B2 (en) 2006-09-12
PE20040983A1 (es) 2005-01-12
AR041093A1 (es) 2005-05-04
AU2003264097A1 (en) 2004-04-30
EP1532141A1 (de) 2005-05-25
PL375627A1 (en) 2005-12-12
RU2324694C2 (ru) 2008-05-20
RU2005109164A (ru) 2006-01-20
DE50313185D1 (de) 2010-11-25
DE10240818A1 (de) 2004-05-13
CY1110913T1 (el) 2015-06-10
CN100390168C (zh) 2008-05-28
ATE484503T1 (de) 2010-10-15
WO2004024725A1 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
DK1500654T3 (da) Benzoxazinonderivater, fremstilling deraf og anvendelse deraf som lægemidler
FR14C0066I2 (fr) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles
NO20033726L (no) Xantin-derivater, fremstilling og anvendelse derav som et medikament
ITTO20010940A0 (it) ,,sedia,,
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20052995D0 (no) 1,5-diaryl-pyrrol-3-karboksamid-derivater, og deres anvendelse som kannabinoid reseptormodulatorer.
NO20055568D0 (no) Substituerte 1,4-diazepiner og anvendelser derav
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20052124D0 (no) Nye 1,4-diazabisykloalkanderivater, deres fremstilling og anvendelse
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
EG23929A (en) Isoxazolines derivatives and their use as antidepressants
NO20030998L (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler
SI1532141T1 (sl) 2-pirolidin-2-il-(1,3,4)-oksadiazolni derivati in njihova uporaba kot antidepresivi
DK1651607T3 (da) 6-(1,1-difluoralkyl)-4-aminopicolinater og deres anvendelse som herbicider
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
DK1492796T3 (da) Substituerede aminoisoxazolinderivater og deres anvendelse som antidepressive midler
NO20053588L (no) Acylaminotiazol-derivater, fremstilling og anvendelse derav som beta-amyloidpeptid-produksjonsinhibitorer.
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
NO20053598L (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.
DK1367055T3 (da) Isoquinolinylcarboxamider og deres anvendelse som krampestillende midler
NO20044090L (no) Substituert 3-fenyl-5-alkoksy-1,3,4-oksadiazol-24neJr, fremstilling derav og anvendelse i medikamenter
DK1537124T3 (da) C-substituerede, tricykliske isoxazolinderivater og deres anvendelse som antidepressive midler
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður